<DOC>
	<DOCNO>NCT00681889</DOCNO>
	<brief_summary>The purpose study determine effectiveness safety ranibizumab ( Lucentis ) treatment corneal neovascularization .</brief_summary>
	<brief_title>Effectiveness Safety Topical Ranibizumab Treatment Corneal Neovascularization ( NV )</brief_title>
	<detailed_description>This open label , single site , uncontrolled , single group assignment , safety/efficacy , Phase I study topical administer ranibizumab subject corneal neovascularization . Ten eyes patient corneal neovascularization recruit . Patients superficial deep corneal neovascularization extend far 2 mm limbus consider .</detailed_description>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Corneal Neovascularization</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 18 year old Patients superficial deep corneal neovascularization extend far 2 mm limbus Has receive investigational therapy within 60 day prior study entry Has receive treatment antiVEGF agent ( intraocular systemic ) within 45 day study entry Concurrent use systemic antiVEGF agent Full thickness lamellar keratoplasty within 90 day prior study entry Ocular surface reconstruction within 90 day prior study entry Other ocular surgery within 90 day prior study entry Corneal ocular surface infection within 90 day prior study entry Ocular periocular malignancy Contact lens ( exclude bandage contact lens ) within 30 day prior study entry Persistent epithelial defect ( &gt; 1mm2 â‰¥14 day duration ) within 30 day prior study entry Systemic , intravitreal , periocular steroid within 30 day prior study entry Change dose/frequency topical steroid and/or NSAIDs within 30 day prior study entry Hypertension : systolic BP &gt; 150 diastolic BP &gt; 90 History thromboembolic event within 6 month prior study entry Current diagnosis diabetes , Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception ( The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch ) Participation another simultaneous medical investigation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>